Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cytogenet Genome Res ; 144(3): 183-9, 2014.
Article in English | MEDLINE | ID: mdl-25661042

ABSTRACT

We report on a 16-year-old girl with a complex phenotype, including intellectual disability, facial dysmorphisms, and obesity. During her infancy, she presented with weak sucking, global developmental delay, and later with excessive eating with central obesity. The girl was clinically diagnosed with probable Prader-Willi syndrome. Chromosomal analysis showed a de novo deletion 46,XX,del(15)(q21q22). However, the use of the Affymetrix CytoScan HD Array defined the exact breakpoints of the deleted 15q21q22 region. The imbalance, about 10.5 Mb in size, is to date the second largest deletion ever described in this chromosomal region. In addition, our patient carries a microdeletion in the 1q44 region and a gain in 9p24. The array result was arr[hg19] 9p24.1(6,619,823-6,749,335)×3, 1q44(248,688,586-248,795,277)×1, 15q21.2 q22.2(50,848,301-61,298,006)×1. Although our patient presents additional chromosomal alterations, we provide a correlation between the clinical findings and the phenotype of the 15q21 deletion syndrome.


Subject(s)
Abnormalities, Multiple/genetics , Chromosome Deletion , Comparative Genomic Hybridization , Developmental Disabilities/genetics , Abnormalities, Multiple/pathology , Adolescent , Chromosomes, Human, Pair 15/genetics , Developmental Disabilities/diagnosis , Female , Humans , In Situ Hybridization, Fluorescence , Phenotype
2.
Pharmacogenet Genomics ; 21(12): 894-901, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21946899

ABSTRACT

N-acetyltransferase 2 (NAT2) catalyzes the bioactivation and/or detoxification of drugs and carcinogens. The aim of this study was to establish the correlation between the NAT2 genotype and the acetylating phenotype in a Mexican population using sulfamethazine as a probe. From a total of 122 individuals, 73 (59.8%) were slow and 49 (40.2%) were fast acetylators. Eleven individuals (9%) had the wild-type genotype (NAT2*4/NAT2*4). The most frequent genotype was NAT2*4/NAT2*5B observed in 20.66% of individuals. In conclusion, our results show that an accurate prediction of the acetylation phenotype by genotyping can be achieved in around half of the population. Further studies with a larger number of individuals are required to establish correlations between phenotype and genotype in half of that patients having a genotype combined with slow/rapid alleles.


Subject(s)
Arylamine N-Acetyltransferase/genetics , Carcinogens/pharmacology , Polymorphism, Genetic , Sulfamethazine/pharmacokinetics , Acetylation , Adult , Aged , Alleles , Arylamine N-Acetyltransferase/metabolism , Female , Genetic Association Studies , Humans , Male , Mexico , Middle Aged , Neoplasms/genetics , Neoplasms/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...